Hyalex Orthopaedics Inc. is pioneering a synthetic cartilage platform known as HYALEX® Cartilage, which aims to restore damaged joint surfaces during surgical procedures. This biomimetic material is specifically designed to mimic the structure and function of native cartilage, addressing a significant gap in current treatment options for patients suffering from cartilage damage. The HYALEX® Knee System represents a key component of this innovative approach, focusing on improving patient outcomes and providing a viable alternative to existing therapies that may not adequately serve those with cartilage injuries.

The company has made significant strides in its development, including receiving FDA Breakthrough Device Designation for the HYALEX® Cartilage System, which highlights its potential to offer substantial benefits over existing treatments. Additionally, Hyalex Orthopaedics has achieved ISO 13485 certification, underscoring its commitment to quality management in the design and manufacturing of medical devices. Through these advancements, Hyalex Orthopaedics aims to transform the landscape of orthopaedic care for patients with cartilage-related issues.

United States

Hyalex Orthopaedics is a venture backed Boston-based medical device start-up focused on developing and commercializing new products that feature HYALEX® materials technology. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

Hyalex Orthopaedics Inc.

Company Details